专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007109515A3 MUTATIONS AND POLYMORPHISMS OF KNOCKDOWN RESISTANCE POLYPEPTIDE 审中-公开
公开(公告)号：WO2007109515A3
公开(公告)日：2007-09-27
申请号：PCT/US2007/064115
申请日：2007-03-16
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： C12Q1/68 , C07K14/71
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the KDR gene. The invention provides new KDR mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the KDR mutations of the invention, expression vectors encoding the KDR mutant polypeptides of the invention and organisms that express the KDR mutant and polymorphic polynucleotides and/or KDR mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the KDR mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.

2. 发明申请

WO2007095032A2 MUTATIONS AND POLYMORPHISMS OF PTK2B 审中-公开
标题翻译： PTK2B的突变和多态性
公开(公告)号：WO2007095032A2
公开(公告)日：2007-08-23
申请号：PCT/US2007/003280
申请日：2007-02-07
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth Wayne , ZHU, Jian , LILLEBERG, Stan
CPC分类号： C12Q1/6886 , C12N9/1205 , C12Q2600/106 , C12Q2600/172
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the PTK2B gene. The invention provides new PTK2B mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the PTK2B mutations of the invention, expression vectors encoding the PTK2B mutant polypeptides of the invention and organisms that express the PTK2B mutant and polymorphic polynucleotides and/or PTK2B mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the PTK2B mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析检测，更具体地涉及PTK2B基因的遗传多态性和突变的方面。本发明提供了新的PTK2B突变和SNP，其可用于诊断和治疗有需要的受试者。因此，本发明的各个方面涉及编码本发明的PTK2B突变的多核苷酸，编码本发明的PTK2B突变体多肽的表达载体和表达PTK2B突变体的生物和表达PTK2B突变体的多态性多核苷酸和/或PTK2B突变体/多态性多肽发明。本发明的各个方面还涉及使用本发明的PTK2B突变和多态性的诊断/诊断方法和试剂盒来鉴定易患疾病的个体或针对药物反应性，副作用或最佳药物剂量对个体进行分类。

3. 发明申请

WO2007058992A2 MUTATIONS AND POLYMORPHISMS OF HDAC6 审中-公开
标题翻译： HDAC6的突变和多态性
公开(公告)号：WO2007058992A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/043899
申请日：2006-11-13
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K48/00 , A61K31/00 , C12N15/63 , A61P35/00
CPC分类号： A61K31/00 , A61K38/15 , A61K48/00 , C12Q1/6886
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC6 gene. The invention provides new HDAC6 mutations and SNPs5 useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC6 mutations of the invention, expression vectors encoding the HDAC6 mutant polypeptides of the invention and organisms that express the HDAC6 mutant and polymorphic ' polynucleotides and/or HDAC6 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC6 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，并且更具体地涉及HDAC6基因的遗传多态性和突变的方面。本发明提供了用于诊断和治疗有需要的受试者的新的HDAC6突变和SNP5。因此，本发明的各个方面涉及编码本发明的HDAC6突变的多核苷酸，编码本发明HDAC6突变多肽的表达载体和表达HDAC6突变体和多态性'多核苷酸和/或HDAC6突变体/多态性多肽的有机体本发明。本发明的各个方面还涉及使用本发明的HDAC6突变和多态性鉴定易患疾病的个体或将个体分类为药物反应性，副作用或最佳药物剂量的诊断/诊断方法和试剂盒。

4. 发明申请

WO2007058991A2 MUTATIONS AND POLYMORPHISMS OF C-ABL 审中-公开
标题翻译： C-ABL的突变和多态性
公开(公告)号：WO2007058991A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/043898
申请日：2006-11-13
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K48/00 , C12Q1/68 , A61P35/00 , A61K31/00 , C12N15/63
CPC分类号： A61K31/00 , C12N9/1205
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the c ABL gene. The invention provides new c ABL mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the c ABL mutations of the invention, expression vectors encoding the c ABL mutant polypeptides of the invention and organisms that express the c ABL mutant and polymorphic polynucleotides and/or c ABL mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the c ABL mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，并且更具体地涉及c ABL基因的遗传多态性和突变的方面。本发明提供了用于诊断和治疗有需要的受试者的新的cABL突变和SNP。因此，本发明的各个方面涉及编码本发明的cABL突变的多核苷酸，编码本发明的cABL突变体多肽的表达载体和表达cABL突变体和多态性多核苷酸和/或cABL突变体/ 本发明的多态性多肽。本发明的各个方面还涉及诊断/诊断方法和试剂盒，其使用本发明的cABL突变和多态性来鉴定易患疾病的个体或关于药物响应性，副作用或最佳药物剂量对个体进行分类

5. 发明申请

WO2007047998A2 MUTATIONS AND POLYMORPHISMS OF HDAC2 审中-公开
标题翻译： HDAC2的突变和多态性
公开(公告)号：WO2007047998A2
公开(公告)日：2007-04-26
申请号：PCT/US2006041168
申请日：2006-10-19
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
发明人： CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
CPC分类号： A61K31/165 , A61K31/19 , C12Q1/6886 , C12Q2600/106 , C12Q2600/172
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC2 gene. The invention provides new HDAC2 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC2 mutations of the invention, expression vectors encoding the HDAC2 mutant polypeptides of the invention and organisms that express the HDAC2 mutant and polymorphic polynucleotides and/or HDAC2 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC2 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析检测，更具体地涉及HDAC2基因的遗传多态性和突变的方面。本发明提供了新的HDAC2突变和SNP，可用于诊断和治疗有需要的受试者。因此，本发明的各个方面涉及编码本发明的HDAC2突变的多核苷酸，编码本发明的HDAC2突变体多肽的表达载体和表达HDAC2突变体的生物和表达HDAC2突变体的多态性多态性和/或HDAC2突变体/多态性多肽发明。本发明的各个方面还涉及使用本发明的HDAC2突变和多态性的诊断/诊断方法和试剂盒来鉴定易患疾病的个体或针对药物反应性，副作用或最佳药物剂量对个体进行分类。

6. 发明申请

WO2007016532A2 MUTATIONS AND POLYMORPHISMS OF HDAC4 审中-公开
标题翻译： HDAC4的突变和多态性
公开(公告)号：WO2007016532A2
公开(公告)日：2007-02-08
申请号：PCT/US2006029851
申请日：2006-07-31
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
发明人： CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
IPC分类号： A61K31/00
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC4 gene. The invention provides new HDAC4 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC4 mutations of the invention, expression vectors encoding the HDAC4 mutant polypeptides of the invention and organisms that express the HDAC4 mutant and polymorphic polynucleotides and/or HDAC4 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC4 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，更具体地涉及HDAC4基因的遗传多态性和突变的方面。本发明提供了可用于诊断和治疗有需要的受试者的新的HDAC4突变和SNP。因此，本发明的各个方面涉及编码本发明的HDAC4突变的多核苷酸，编码本发明的HDAC4突变体多肽的表达载体和表达HDAC4突变体的生物和表达HDAC4突变体的多态性多态性和/或HDAC4突变体/多态性多肽发明。本发明的各个方面进一步涉及使用本发明的HDAC4突变和多态性的诊断/治疗方法和试剂盒来识别易患疾病的个体或者关于药物反应性，副作用或最佳药物剂量对个体进行分类。

7. 发明申请

WO2006050945A3 TUBULIN MUTATION DIAGNOSTIC 审中-公开
标题翻译： TUBULIN MUTATION诊断
公开(公告)号：WO2006050945A3
公开(公告)日：2007-01-25
申请号：PCT/EP2005012044
申请日：2005-11-10
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER KENNETH WAYNE , WARTMANN MARKUS , LILLEBERG STAN , ZHU JIAN
发明人： CULVER KENNETH WAYNE , WARTMANN MARKUS , LILLEBERG STAN , ZHU JIAN
IPC分类号： C12Q1/68 , C07K14/47 , G01N33/50 , G01N33/68
CPC分类号： C12Q1/6883 , C07K14/47 , C12Q2600/106 , C12Q2600/156 , G01N33/5008 , G01N33/5011 , G01N33/68 , G01N33/6848 , G01N2800/52
摘要： The present invention relates to methods for determining the potential of a subject to respond to a particular therapeutic agent, by determining the presence of one or more nucleotide or amino acid variants in the ß-tubulin gene or protein. Also provided are methods for treating subjects whose potential to respond to a therapeutic agent has been evaluated. For use in the methods of the invention, there are provided variants of the ß-tubulin gene, variants of the ß-tubulin protein, nucleic acid molecules and agents which bind to the variant ß-tubulin nucleic acid molecules and variant ß-tubulin protein, respectively, and kits comprising the same.
摘要翻译：本发明涉及通过测定β-微管蛋白基因或蛋白质中一个或多个核苷酸或氨基酸变体的存在来确定受试者对特定治疗剂的响应潜力的方法。还提供了用于治疗对治疗剂有响应的潜能的方法。为了用于本发明的方法，提供β-微管蛋白基因的变体，β-微管蛋白的变体，结合变体β-微管蛋白核酸分子和变体β-微管蛋白的核酸分子和试剂，以及包含其的试剂盒。

8. 发明申请

WO2005053704A1 METHOD FOR PREDICTING DRUG RESPONSIVENESS IN MYELOID NEOPLASMS 审中-公开
标题翻译：用于预测MYELOID NEOPLASMS中药物应答的方法
公开(公告)号：WO2005053704A1
公开(公告)日：2005-06-16
申请号：PCT/EP2004/013588
申请日：2004-11-30
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne
发明人： CULVER, Kenneth, Wayne
IPC分类号： A61K31/553
CPC分类号： A61K31/553
摘要： This invention provides methods to predict from samples of blood or bone marrow which patients with myeloid neoplasms will show a good therapeutic response to therapeutic agents that work, at least in part, by inducing apoptosis in tumour cells. These methods can help determine treatment choices and select patients for drug studies.
摘要翻译：本发明提供从血液或骨髓样品中预测的方法，所述骨髓瘤患者对治疗剂显示良好的治疗反应，所述治疗剂至少部分通过诱导肿瘤细胞凋亡而起作用。这些方法可以帮助确定治疗选择并选择患者进行药物研究。

9. 发明申请

WO2007127524A2 MUTATIONS AND POLYMORPHISMS OF INSR 审中-公开
标题翻译： INSR的突变和多态性
公开(公告)号：WO2007127524A2
公开(公告)日：2007-11-08
申请号：PCT/US2007/062636
申请日：2007-02-23
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K31/00
CPC分类号： G01N33/57484 , C07K14/72 , C12N15/1138 , C12N2310/11 , C12N2310/111 , G01N2333/72
摘要： This invention relates testing of in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the INSR gene. The invention provides new INSR mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the INSR mutations of the invention, expression vectors encoding the INSR mutant polypeptides of the invention and organisms that express the INSR mutant and polymorphic polynucleotides and/or INSR mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the INSR mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明涉及体外的测试，更具体地涉及INSR基因的遗传多态性和突变的方面。本发明提供了可用于诊断和治疗有需要的受试者的新的INSR突变和SNP。因此，本发明的各个方面涉及编码本发明的INSR突变的多核苷酸，编码本发明的INSR突变体多肽的表达载体和表达INSR突变体和多态性多核苷酸和/或INSR突变体/多态性多肽的生物体发明。本发明的各个方面进一步涉及使用本发明的INSR突变和多态性的诊断/鉴别方法和试剂盒来鉴定易患疾病的个体或在药物反应性，副作用或最佳药物剂量方面对个体进行分类。

10. 发明申请

WO2007121017A2 MUTATIONS AND POLYMORPHISMS OF FMS-LIKE TYROSINE KINASE 4 审中-公开
标题翻译： FMS样酪氨酸激酶的突变和多态性4
公开(公告)号：WO2007121017A2
公开(公告)日：2007-10-25
申请号：PCT/US2007064116
申请日：2007-03-16
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
发明人： CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
CPC分类号： C12Q1/6886 , C12Q2600/106
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the FLT 4 gene. The invention provides new FLT 4 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the FLT 4 mutations of the invention, expression vectors encoding the FLT 4 mutant polypeptides of the invention and organisms that express the FLT 4 mutant and polymorphic polynucleotides and/or FLT 4 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the FLT 4 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，更具体地涉及FLT4基因的遗传多态性和突变的方面。本发明提供了新的FLT4突变和SNP，可用于诊断和治疗有需要的受试者。因此，本发明的各个方面涉及编码本发明的FLT4突变的多核苷酸，编码本发明的FLT4突变体多肽的表达载体和表达FLT4突变体和多态性多核苷酸和/或FLT4突变体/ 本发明的多态性多肽。本发明的各个方面进一步涉及使用本发明的FLT4突变和多态性的诊断/非特异性方法和试剂盒来识别易患疾病的个体或在药物反应性，副作用或最佳药物剂量方面对个体进行分类。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式